Calithera shares early-stage data for cystic fibrosis candidate
AndreyPopov/iStock via Getty Images
- Calithera Biosciences (NASDAQ:CALA) has added ~4.7%
in the pre-market after the company reported interim Phase 1b data from a dose-escalation trial designed to evaluate CB-280 in adults with cystic fibrosis (CF). - Data…
